We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

5 hedge funds and large institutions have $1.39M invested in Decoy Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding

Funds holding: 1 → 5 (+4)

29% more capital invested

Capital invested by funds: $1.08M → $1.39M (+$310K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
5
Holders Change
+4
Holders Change %
+400%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DWA
Douglass Winthrop Advisors
New York
+$682K
2
FAIM
Financial Advocates Investment Management
Washington
+$341K
3
LNWWM
Laird Norton Wetherby Wealth Management
California
+$341K
4
TSS
Two Sigma Securities
New York
+$341K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$97K
2
AIP
Ahrens Investment Partners
Louisiana
-$78K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$66K
4
Northern Trust
Northern Trust
Illinois
-$12K
5
Creative Planning
Creative Planning
Kansas
-$11K

DCOY Hedge Fund Activity: Q3 2019 in Review

5 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2019, worth a combined $1.39M — up 29% from $1.08M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new DCOY positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Douglass Winthrop Advisors, opening a new position worth an estimated $682K. The largest seller was Geode Capital Management, cutting an estimated $97K.

  • 5 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2019, up from 1 in Q2 2019.
  • Funds reported $1.39M of Decoy Therapeutics stock for Q3 2019, up 29% quarter-over-quarter.
  • 4 funds opened new Decoy Therapeutics positions in Q3 2019 and 0 closed out, a net change of +4 holders.
  • The largest Decoy Therapeutics buyer in Q3 2019 was Douglass Winthrop Advisors, an estimated $682K added.
  • The largest Decoy Therapeutics seller in Q3 2019 was Geode Capital Management, an estimated $97K sold.

Based on aggregated 13F filings for Q3 2019.